Shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) have earned an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.
Brokerages have set a 12-month consensus target price of $11.16 for the company and are predicting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also assigned DelMar Pharmaceuticals an industry rank of 197 out of 265 based on the ratings given to related companies.
Separately, HC Wainwright set a $12.00 price target on shares of DelMar Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, January 4th.
A hedge fund recently bought a new stake in DelMar Pharmaceuticals stock. Sabby Management LLC acquired a new stake in shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 645,390 shares of the company’s stock, valued at approximately $1,484,000. Sabby Management LLC owned 4.79% of DelMar Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 17.03% of the company’s stock.
WARNING: “Zacks: Brokerages Set $11.16 Price Target for DelMar Pharmaceuticals Inc (DMPI)” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.chaffeybreeze.com/2018/02/15/zacks-brokerages-set-11-16-price-target-for-delmar-pharmaceuticals-inc-dmpi.html.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.